Organ-on-a-chip technology could eradicate animal testing
Researchers at the University of Rochester are developing an organ-on-a-chip platform designed to improve the prediction of dangerous side effects from cancer immunotherapies. The work, led by the university’s Translational Center for Barrier Microphysiological Systems (TraCe-bMPS), aims to provide drug developers with human-based testing tools that could eventually support regulatory submissions to the US Food and Drug Administration (FDA). The team is using tissue chips containing human cells to investigate adverse immune reactions that conventional animal models can struggle to reproduce. The technology combines modular µSiM chips, developed by the Center’s director James McGrath, with integrated sensors developed by Benjamin Miller to measure barrier function and inflammatory signalling in real time. The project has reached an important regulatory milestone after being accepted into the FDA’s Innovative Science and Technology Approaches for New Drugs (ISTAND) programme. The programme is intended to help assess innovative drug development tools for potential regulatory use. If the Rochester platform ultimately achieves FDA qualification, pharmaceutical companies could use its data alongside other evidence when developing and seeking approval for new medicines. …









